I.Essadi, Y.Sbitti, M.Ichou and H.Errihani
Kaposi’s sarcoma (KS) is an opportunistic tumor proliferation Multicenter cells derived from lymphatic endothelium, infected with human herpes virus 8 (HHV-8). It is a heterogeneous disease distribution, which can be linked to poor prognosis. HHV-8 infection and immunosuppression are essential to its development [1,2]. These two elements are constant in the four clinical-epidemiological forms of KS: classical form, originally described by Moritz Kaposi typically affecting elderly men of Mediterranean, the endemic presence in Southern Africa, the epidemic form in patients infected HIV, and, finally, the MK complicating iatrogenic immunosuppression, particularly after organ transplantation [3]. This work exposes the real place of chemotherapy in adult patients with Kaposi sarcoma, among the available therapeutic means.
இந்தக் கட்டுரையைப் பகிரவும்